AZD9833 + AZD9833 Placebo + Anastrozole + Anastrozole placebo + Letrozole + Letrozole placebo + Palbociclib + Abemaciclib + Luteinizing hormone-releasing hormone (LHRH) agonist + Ribociclib
Phase 3Active 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
ER-Positive HER2-Negative Breast Cancer
Conditions
ER-Positive HER2-Negative Breast Cancer
Trial Timeline
Jun 30, 2021 → Nov 26, 2027
NCT ID
NCT04964934About AZD9833 + AZD9833 Placebo + Anastrozole + Anastrozole placebo + Letrozole + Letrozole placebo + Palbociclib + Abemaciclib + Luteinizing hormone-releasing hormone (LHRH) agonist + Ribociclib
AZD9833 + AZD9833 Placebo + Anastrozole + Anastrozole placebo + Letrozole + Letrozole placebo + Palbociclib + Abemaciclib + Luteinizing hormone-releasing hormone (LHRH) agonist + Ribociclib is a phase 3 stage product being developed by AstraZeneca for ER-Positive HER2-Negative Breast Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT04964934. Target conditions include ER-Positive HER2-Negative Breast Cancer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04964934 | Phase 3 | Active |
Competing Products
6 competing products in ER-Positive HER2-Negative Breast Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Fulvestrant Run-In | Eli Lilly | Phase 2 | 52 |
| AZD9833 + Anastrozole + Anastrozole placebo + AZD9833 placebo + Palbociclib + Luteinizing hormone-releasing hormone (LHRH) agonist | AstraZeneca | Phase 3 | 77 |
| [14C]AZD9833 Oral Solution, 75 mg | AstraZeneca | Phase 1 | 33 |
| AZD9833 + Fulvestrant | AstraZeneca | Phase 2 | 52 |
| Giredestrant + Abemaciclib + Ipatasertib + Inavolisib + Ribociclib + Everolimus + Samuraciclib + PH FDC SC + Palbociclib + Atezolizumab | Roche | Phase 1/2 | 41 |
| Onapristone + Fulvestrant | Context Therapeutics | Phase 2 | 44 |